Clover Health (CLOV) Q2 2026 earnings review
The Strategy Pays Off: Scaling Growth and GAAP Profitability Together
Clover Health delivered a textbook 'beat and raise' quarter, proving that its 2025 strategy of trading near-term margins for aggressive market share was the right move. The company reported $28 million in Q2 GAAP Net Income—a massive $39 million positive swing year-over-year—while growing Medicare Advantage membership by 48%. The maturation of the large 2025 member cohort, combined with the financial tailwinds of a 4-Star payment year, has triggered a severe positive inflection in the business. Management confidently raised full-year 2026 guidance across all key metrics, including revenue, Adjusted EBITDA, and GAAP Net Income.
🐂 Bull Case
The core thesis is intact: new members are an upfront investment that yield compounding returns. The massive influx of new members that crushed 2025 margins has successfully matured into a highly profitable returning cohort for 2026.
The company is successfully scaling without bloating its cost base. Adjusted SG&A dropped 220 basis points year-over-year to 15.1% of revenue in Q2, demonstrating real operating leverage driven by AI automation and scale efficiencies.
🐻 Bear Case
Unpaid claims on the balance sheet surged 63% from December 2025 to $250.9 million, outpacing membership growth. This could indicate either delayed claims processing or a buildup of unexpected medical costs.
Despite strong headline numbers, the Medicare Advantage industry is still grappling with elevated outpatient utilization and structural Part D cost changes from the Inflation Reduction Act, requiring perfect ongoing execution.
⚖️ Verdict: 🟢🟢
Bullish. Clover achieved the rarest feat in the current Medicare Advantage landscape: hyper-growth (48% YoY membership) combined with a structural transition to GAAP profitability. The raised guidance signals management's confidence that this inflection is durable.
Key Themes
The 4-Star Tailwinds Arrive
Management previously telegraphed that 2026 would be a transformational year due to their PPO plans achieving a 4-Star rating for the payment year. This rating unlocked significant financial tailwinds, directly feeding the $40.9 million Adjusted EBITDA generated in Q2 (up 139% YoY). The combination of a higher baseline payment and the natural margin expansion of the maturing 2025 member cohort is working exactly as planned.
Ruthless SG&A Efficiency
Growth is only valuable if costs scale slower than revenue. Clover is delivering here: Adjusted SG&A as a percentage of Total Revenues fell to 15.1% in Q2 2026, a 220 basis point improvement from 17.3% a year ago. Management cites scale efficiencies, optimized vendor contracts, and the deployment of AI-driven automation as the primary drivers of this durable cost advantage.
Capitalizing on Competitor Retreats
As major legacy competitors retreat from full-risk, wide-network PPO plans due to margin pressures, Clover is aggressively taking market share. Q2 average membership hit 156,840, up 48.7% YoY. Because Clover's technology is specifically built to manage decentralized PPO networks, they are vacuuming up lives in a segment where peers are structurally disadvantaged.
Clover Assistant Proving its Worth
Clover Assistant is no longer just a narrative talking point; it is actively defending the bottom line. The AI-powered platform aggregates patient data to support clinical decision-making. By managing care at the point of the physician encounter, it is enabling earlier intervention for chronic diseases. Management believes this differentiated, data-driven approach is the bedrock of their ability to run wide-network PPOs profitably.
Unpaid Claims Balance Spike Contradicts Perfect Narrative
While the income statement looks pristine, the balance sheet raises a flag. Unpaid claims jumped from $153.3 million at the end of 2025 to $250.9 million at the end of Q2 2026—a 63% increase. Given membership grew roughly 48% over the same timeframe, the liability is growing faster than the patient base. This implies either conservative reserving by the new CFO, or a backlog of delayed, high-severity claims that could pressure the Medical Care Ratio (MCR) in the back half of the year.
Macro: IRA Part D Changes and Outpatient Intensity
The broader Medicare Advantage macro environment remains hostile. The industry is currently dealing with the rollout of the Inflation Reduction Act's (IRA) changes to Part D, alongside elevated outpatient utilization and service intensity. While Clover has navigated this better than peers in H1 2026, the lack of a historical baseline for new Part D dynamics leaves modeling variability for the rest of the year.
Counterpart Health Execution Risk
Clover is investing heavily in Counterpart Health (its SaaS offering for external payers). While this is pitched as a high-margin 'blue ocean' opportunity to monetize the Clover Assistant platform, it currently acts as a drag on SG&A expenses. The company needs to prove it can scale external lives and generate meaningful SaaS revenue to justify the ongoing internal investment.
Other KPIs
Accelerating. Up a massive 53.6% from $99.6 million in Q2 2025. This underscores that revenue growth is translating directly into core operational profitability before administrative expenses are factored in.
Stable/Improving. Down 80 basis points from 88.4% in Q2 2025. A sub-88% BER for a rapidly growing, full-risk PPO plan is exceptionally strong in the current regulatory environment, reflecting strict medical cost management.
Stable. Up 13.8% YoY from $389.3 million. More importantly, operating cash flow funded the growth, as the company maintains a zero-debt balance sheet and avoids dilutive capital raises.
Guidance
Accelerating. The midpoint of $2.96 billion represents 54% year-over-year growth. This is a raise from the previous guidance of $2.81 - $2.92 billion, reflecting extreme confidence in membership retention and revenue capture in the back half of the year.
Accelerating. Raised significantly from the previous range of $50 - $70 million. With $81.2 million already generated in H1 2026, this guidance implies management expects EBITDA to be roughly flat to slightly negative in H2, likely baking in heavy conservatism for seasonal medical utilization or Part D uncertainties.
Reversing. The company raised its GAAP Net Income target from $0 - $20 million to $20 - $35 million. This cements 2026 as the foundational year of GAAP profitability, completely reversing the narrative of cash-burning growth that defined the company in earlier years.
Accelerating. Raised from 154,000 - 158,000. Represents 47% YoY growth at the midpoint. This tightens the range at the high end, reflecting low churn and strong mid-year clinical engagement.
Key Questions
Unpaid Claims Buildup
Unpaid claims on the balance sheet grew 63% over the last six months to $251 million, meaningfully outpacing your membership growth. Is this a result of intentional reserving conservatism by the new CFO, or are you seeing a delay in claims processing / higher severity in the tail?
H2 Adjusted EBITDA Implied Deceleration
You printed $81 million in Adjusted EBITDA in the first half of the year, yet your raised full-year guide is $70 to $85 million. Can you unpack the specific headwinds or conservatism baked into H2 that implies zero or negative EBITDA generation for the remainder of the year?
Counterpart Health Traction
You noted previously that Counterpart Health is a 'blue ocean' opportunity. Given the ongoing SG&A investments to build out that go-to-market team, when should investors expect to see material, breakout SaaS revenue contributions from this segment?